top of page
Glass Ceiling


Aro Biotherapeutics Sukumar Sakamuri.jpg
Sukumar Sakamuri, PhD

Chief Technology Officer

Sukumar Sakamuri, Ph.D., brings over 20 years of drug discovery and entrepreneurial leadership to Aro Biotherapeutics. Prior to joining Aro, Dr. Sakamuri served as Vice President and Head of Chemistry at Ambrx working on its ADC technology platform. He was responsible for discovering multiple pre-clinical candidates and advancing them toward the clinic.  Before Ambrx, Dr. Sakamuri co-founded Tollnine, an immuno-oncology company working on antibody-oligonucleotide conjugates. He is co-inventor of the Tollnine technology platform, served as Vice President, Chemistry and was responsible for transitioning Tollnine into a pre-clinical development company. Prior to Tollnine, he served as Executive Director and Head of Chemistry at Solstice Biologics. As a founding employee, he built the Solstice chemistry team and invented best-in-class siRNA-GalNAc conjugates for rare and genetic diseases. Prior to Solstice, Dr. Sakamuri served in increasing responsibility at Traversa Therapeutics, Orchid Pharma, CovX and Morphochem. Dr. Sakamuri is an inventor and author of over 45 patents, patent applications, and publications. He conducted postdoctoral research in medicinal chemistry at Georgetown University and holds a Ph.D. in organic chemistry from the Indian Institute of Chemical Technology, India.

bottom of page